Towards inhibitors of glycosyltransferases: 
A novel approach to the synthesis of 3-acetamido- 
3-deoxy-D-psicofuranose derivatives

Maroš Bella*1, Miroslav Koóš1 and Chun-Hung Lin2

Full Research Paper

Address:
1Institute of Chemistry, Slovak Academy of Sciences, Dúbravská 
cesta 9, SK-845 38, Bratislava, Slovakia and 2Institute of Biological 
Chemistry, Academia Sinica, No. 128 Academia Road Sec. 2, Taipei 
11529, Taiwan

Email:
Maroš Bella* - chemmajo@savba.sk

* Corresponding author

Keywords:
glycosyltransferases; inhibitors; D-psicofuranose; synthesis; 
thioglycosylation

Abstract
A novel synthetic strategy leading to 3-acetamido-3-deoxy-D-psicofuranose 9 is presented. The latter compound, after some 
manipulations, was transformed into fully protected 3-acetamido-3-deoxy-D-psicofuranose 11 as a potential substrate for the syn-
thesis of N-acetylglucosaminyltransferase inhibitors designed by computational methods. After the attempted thioglycosylation of 
11 with EtSH in the presence of BF3·OEt2, 2-methylloxazoline derivatives 13 and 14 were isolated.

Introduction
Glycosyltransferases (GTs) belong to a family of enzymes that 
are responsible for the biosynthesis of complex oligo-
saccharides, glycoproteins and other glycoconjugates in 
mammalian biological systems. These glycoconjugates are 
operating in the cell and on the cell surface, particularly as 
glycoproteins, and are involved in many vital biological 
processes, such as cell–cell communication, signal transduction, 
activation and response of the immune system etc. [1,2]. On the 
other hand, an uncontrolled glycosylation caused by genetic 
mutations of GTs leads to structural changes in various glyco-
conjugates which contribute to many mammalian diseases [3,4]. 
In addition, the role played by the glycoconjugates changes 
markedly during disease development such as malignant trans-
formation [5], cancer cell proliferation and metastases spreading 
[6]. Since glycosyltransferases (GTs) are entailed in the biosyn-
thesis of glycans and glycoconjugates, which are involved in 
these disease processes, inhibitors of GTs are of great therapeu-
tic potential and attract remarkable interest for drug devel-
opment.

Although the mechanism of reactions catalyzed by glycosyl-
transferases has been investigated thoroughly, many aspects of 
the catalytic mechanism remain unknown [7]. In general, GTs 
transfer sugar nucleotide donors onto suitable acceptors during
the biosynthesis of glycans and glycoconjugates [8]. Both donor and acceptor substrates are recognized by GTs binding pockets. For instance, in the course of biosynthesis of complex and hybrid oligosaccharides, the insertion of an N-acetylglucosaminyl moiety (GlcNAc-) into an oligosaccharide chain was identified as the crucial step catalyzed by N-acetylglucosaminyltransferases (GnTs) in the presence of a metal co-factor. In this catalytic reaction, UDP-GlcNAc [uridine 5′-(2-acetamido-2-deoxy-D-glucopyranosyl diphosphate)] acts as the donor of the GlcNAc residue while a hydroxy group situated at a specific site of the growing oligosaccharide chain serves as the acceptor [9].

The target-directed search for effective GnTs inhibitors based on the rational design of model compounds remains a difficult task due to the complexity of the GnTs catalytic mechanism. The main reasons originating from the complex character of the catalytic mechanism which complicate the search for GnTs inhibitors are a) participation of four components in the transition state (sugar donor, acceptor, nucleotide and metal co-factor), b) weak binding of the enzymes to natural substrates, and c) lack of structural data [10]. Various methods have been applied in order to unveil effective GTs inhibitors [11-16]. The most important approaches are based on the design of acceptor analogues, donor analogues and transition state mimetics. Despite all the effort and the numerous GTs inhibitors identified, only a few achieved significant activity. On the basis of the previous investigations, a new class of GTs inhibitors imitating carbohydrates has been revealed [17]. These structurally modified carbohydrates are designed to simulate the shape and functionality of the natural substrates in the ground and/or the transition state (TS) of the enzymatic reaction [14]. In the case of GTs inhibitors, the carbohydrate mimetics that imitate the TS of the enzymatic reactions should exhibit a higher inhibition activity than the natural carbohydrate substrates [9,16]. Investigations of the catalytic mechanism of inverting glycosyltransferases [18] and N-acetylglucosaminyltransferase I [19] by employing ab initio calculations resulted in the design of inhibitors based on carbohydrate mimetics that simulate the transition state of the enzymatic reaction (Figure 1).

Within the structure of the proposed inhibitors of N-acetylglucosaminyltransferases (Figure 1), the ethyl, benzyl and/or phenyl groups imitate the acceptor substrate and the “1-thio” linker provides the proper distance between the “donor” and the “acceptor” together with the charge distribution as it was calculated for the TS [9,10].

In this contribution, attention is focused on the synthesis of the saccharide moiety of potential GnTs inhibitors (framed structure in Figure 1). In this respect, a novel approach to 3-acetamido-3-deoxy-D-psicofuranose derivatives, based on the transformation of D-mannose, is described. In addition, the thioglycosylation of fully protected 3-acetamido-3-deoxy-D-psicofuranose 11 with ethanethiol was examined under various conditions.

Results and Discussion

The synthesis of the saccharide moiety of potential GnTs inhibitors started from commercially available D-mannose. The latter was transformed into suitably protected 1,2:4,5-di-O-isopropylidene-6-O-pivaloyl-D-mannitol (1) in three steps by the procedures described in the literature [20-22]. The standard preparation of mesylate with methanesulfonyl chloride and Et$_3$N as base smoothly provided 1,2:4,5-di-O-isopropylidene-3-O-methanesulfonyl-6-O-pivaloyl-D-mannitol (2) in 93% yield (Scheme 1).

In the next step, the treatment of mesylate 2 with sodium azide in refluxing aqueous DMF afforded 3-azido-3-deoxy-1,2:4,5-di-O-isopropylidene-6-O-pivaloyl-D-altritol (3) in 23% yield. The addition of a catalytic amount of tetrabutylammonium azide in situ did not improve the yields of the substitution. In the course of the nucleophilic substitution, unidentified elimination products were observed as the prevailing constituents of the reaction mixture together with the desired 3-azido derivative 3. The majority of the byproducts were separated by column chromatography on silica gel (EtOAc/hexane 1:10). A complete separation of the elimination products from 3 was not necessary since they were readily removed in the next step. An analytically pure sample of 3 was obtained by additional column chromatography. In order to increase the yield of azide 3 by replacing 3-O-mesylate 2 with the corresponding 3-O-triflate in the nucleophilic substitution reaction with sodium azide, the O-protected mannitol derivative 1 was treated with triflic anhydride in the presence of pyridine. However, the resulting 3-O-triflate was unstable and decomposed rapidly after the work-up. On the other hand, an...
1549

Scheme 1: Reagents and conditions: a) MsCl, Et$_3$N, CH$_2$Cl$_2$, 0 °C → rt, overnight, 93%; b) NaN$_3$, H$_2$O/DMF 1:20 (v/v), reflux, 9 h, 23%; c) i: Zn/NH$_4$Cl, H$_2$O/EtOH 1:3 (v/v), rt, 2 h, ii: AcCl, pyridine, CH$_2$Cl$_2$, rt, 30 min, 80% (2 steps); d) 70% AcOH, rt, overnight, 71%; e) TrCl, Et$_3$N, CH$_2$Cl$_2$, 0 °C → rt, overnight, 88%; f) DMP, CH$_2$Cl$_2$, rt, overnight, 95%.

1550

1551

attempted tosylation of alcohol 1 using TsCl and pyridine in CH$_2$Cl$_2$ did not proceed, probably due to steric hindrance, and only the starting material was recovered. Next, the azide 3 (contaminated with some elimination products) was subjected to reduction with powdered Zn and NH$_4$Cl as reducing agents [23] followed by acetylation to afford 3-acetamido-3-deoxy-1,2:4,5-di-O-isopropylidene-6-O-pivaloyl-D-altritol (4) in a good yield. It should be mentioned that the reduction of compound 3 under the Staudinger protocol (PPh$_3$, H$_2$O/THF) was found to be slow and ineffective. The following selective acidic hydrolysis of 1,2-O-isopropylidene ketal in 4 using 70% AcOH led to 3-acetamido-3-deoxy-4,5-O-isopropylidene-6-O-pivaloyl-D-altritol (5). Subsequently, the selective protection of the primary hydroxy group in diol 5 as trityl ether under standard conditions followed by the oxidation of the free secondary hydroxy group in 3-acetamido-3-deoxy-4,5-O-isopropylidene-6-O-pivaloyl-1-O-trityl-D-altritol (6) with Dess–Martin periodinane yielded a protected open-chain form of 3-acetamido-3-deoxy-6-O-pivaloyl-α/β-D-psicofuranose derivatives bearing variously protected or unprotected hydroxy groups on the furanose ring. For example, the treatment of 7 with concentrated H$_2$SO$_4$ in methanol resulted in a mixture of anomeric methyl 3-acetamido-3-deoxy-6-O-pivaloyl-α/β-D-psicofuranosides (8) in 71% yield (Scheme 2).

Based on the integration of the $^1$H NMR signals of the acetamide group in derivatives 8, a 3:2 ratio of the anomers was determined, albeit without the exact assignment of anomic configurations to particular anomers. In the context of the synthesis of the saccharide part of GnTs inhibitors, psicose derivative 7 was subjected to a simultaneous hydrolysis of the trityl ether and the 4,5-O-isopropylidene ketal with concentrated H$_2$SO$_4$ in 70% AcOH to afford 3-acetamido-3-deoxy-6-O-pivaloyl-α/β-D-psicofuranose (9) in 84% yield. In the next step, the hydroxy groups of 9 in positions 1 and 2 were protected as isopropylidene ketal. Although both anomers were formed together with 3-acetamido-3-deoxy-4,5-O-isopropylidene-6-O-pivaloyl-D-psicose as a byproduct originating from isopropylidene denaturation of the open-chain form of 9, only the α-anomer, namely 3-acetamido-3-deoxy-1,2-O-isopropylidene-6-O-pivaloyl-α-D-psicofuranose (10), was isolated in 63% yield. The β-anomer was detected in a negligible amount and could not be separated from the above-mentioned byproduct. Acetylation of the 4-hydroxy group in derivative 10 under standard conditions yielded fully protected 3-acetamido-4-O-acetyl-3-deoxy-1,2-O-isopropylidene-6-O-pivaloyl-α-D-psicofuranose (11) as the suitable substrate for thioglycosylation. Attempts to determine the configuration at the anomeric center in compounds 10 or 11 by employing NOE NMR technique were ambiguous. Although both derivatives 10 and 11 were crystalline solids, it was not possible to obtain suitable crystals for single-crystal X-ray analysis. However, removal of the pivaloyl group from derivative 10 afforded 3-acetamido-3-deoxy-1,2-O-
isopropylidene-α-D-psicofuranose (12) which, after crystallization (EtOAc/hexane 1:2), afforded crystals suitable for X-ray analysis. This unambiguously confirmed the α-configuration at C-2 of furanose 12 (Figure 2). Consequently, based on this information, the α-configurations at the anomic center of derivative 10 as well as 11 were determined.

The crucial step leading to the target saccharide part of potential GnTs inhibitors represents the thioglycosylation of the fully protected psicofuranose derivative 11 with ethanethiol as the model thiolating agent. However, the treatment of 11 with EtSH and BF₃·OEt₂ led predominantly to 2-methyloxazoline derivatives 13 and 14, while the required ethyl 3-acetamido-3-deoxy-6-O-pivaloyl-2-thio-β-D-psicofuranoside (15) was detected only in traces as a mixture with the corresponding α-anomer 16 (Scheme 3).

Further attempts to achieve the thioglycosylation of D-psicofuranose derivative 11 under various conditions, including EtSH/TMSOTf/CH₂Cl₂, EtSH/TMSOTf and EtSH/CSA/CH₂Cl₂ did not improve the yield of the required 2-thio-β-D-psicofuranoside derivative 15.
X-ray analysis

Single crystals (stable at ambient temperature) that were suitable for X-ray diffraction measurements were obtained by slow crystallization of 12 from EtOAc/hexane 1:2 with cooling in a refrigerator. The preliminary orientation matrices and final cell parameters were obtained using the Siemens SMART and Siemens SAINT software [24]. The data were empirically corrected for absorption and other effects using the SADABS program [25]. The crystal and experimental data for compound 12 are summarized in Table 1. The structure was resolved by direct methods and refined by full-matrix least-squares on all \( F^2 \) data using SHELXS-97 [26] and SHELXL2013 [27]. The non-H atoms were refined anisotropically.

Based on the calculated values of the ring-puckering parameters [28] \( Q = 0.376(2) \) Å and \( \Phi = 50.64(9)^\circ \) and relevant torsion angles (Table 2), the five-membered 1,3-dioxolane ring (O2–C6–C1–O3–C7), the puckering parameters \( Q = 0.288(2) \) Å and \( \Phi = 15.7(5)^\circ \) and relevant torsion angles (Table 2) are indicative of \( ^1T_1 \) conformation \((C^2T_C1, \text{twisted on C1–C2, C1-exo, C2-end})\). For the five-membered 1,3-dioxolane ring (O2–C6–C1–O3–C7), the puckering parameters \( Q = 0.288(2) \) Å and \( \Phi = 15.7(5)^\circ \) and relevant torsion angles (Table 2) are indicative of \( ^1T_1 \) conformation \((O^2T_C6, \text{twisted on O2–C6, C6-exo, C2-end})\).

In summary, a new synthetic strategy leading to the formation of a 3-acetamido-3-deoxy-D-psicofuranose frame is presented. The attempted thio glycosylation of fully protected 3-acetamido-3-deoxy-a-D-psicofuranose 11 resulted in ring closure of the acetamido group, affording 2-methylxazoline derivatives 13.

### Table 1: Crystallographic and experimental data\(^a\) for compound 12.

| Crystal data |
|-------------|
| Empirical formula | \( \text{C}_{11}\text{H}_{19}\text{NO}_{6} \) |
| Formula weight/mass | 261.27 |
| Crystal size | \( 0.420 \times 0.060 \times 0.040 \) mm |
| Crystal description | needle |
| Crystal colour | colourless |
| Crystal system | monoclinic |
| Space group | C2 |
| Unit cell dimensions | \( a = 18.8306(8) \) Å \<br\>\( b = 5.4573(2) \) Å \<br\>\( c = 13.1363(6) \) Å |
| Volume | 1234.02(9) Å\(^3\) |
| Z | 4 |
| Calculated density | 1.406 Mg/m\(^3\) |
| Absorption coefficient | 0.114 mm\(^{-1}\) |
| \( F(000) \) | 560 |

### Table 2: Relevant torsion angles (\(^\circ\)) for the five-membered furanose ring, five-membered 1,3-dioxolane ring and anomeric center in compound 12.

| Ring | Torsion angle | Value |
|------|---------------|-------|
| Furanose | O1–C1–C2–C3 | 39.5(2) |
| C1–C2–C3–C4 | 28.8(2) |
| C2–C3–C4–C1 | 9.0(2) |
| C3–C4–O1–C1 | 16.6(2) |
| C4–O1–C1–C2 | 34.9(2) |
| C5–O1–C1–C2 | \(-34.9(2)\) |
| 1,3-Dioxolane | O2–C6–C1–O3 | 49.4(2) |
| C6–C1–O3–C7 | 27.2(2) |
| C7–O3–C1–C2 | 11.2(2) |
| C7–O3–C1–C2 | \(-31.6(2)\) |
| Anomeric center | C3–C2–C1–O3 | \(-78.7(2)\) |
| C3–C2–C1–O3 | 162.24(18) |
| C4–O1–C1–C3 | 83.7(2) |
| C4–O1–C1–C3 | \(-161.35(19)\) |
| N1–C2–C1–O3 | 44.1(2) |
| N1–C2–C1–C6 | \(-75.0(2)\) |

\(^a\)Standard deviations are given in parentheses.
Acknowledgements

The financial support received from the Slovak Research and Development Agency (Grant no. APVV-0484-12), Scientific Grant Agency (Grant nos. VEGA 2/0064/15 and 1/0962/12) and the SAS-Taiwan project (Grant no. SAS-NSC 2012/8) is gratefully acknowledged. This contribution is the result of the project implementation: Centre of Excellence for Glycomics, ITMS26240120031, supported by the Research & Development Operational Programme funded by the ERDF. The technical assistance afforded by Ms Beáta Kalivodová is gratefully acknowledged.

References

1. Varki, A.; Cummings, R. D.; Esko, J. D.; Freeze, H. H.; Stanley, P. Essentials of Glycobiology, 2nd ed.; Cold Spring Harbor Laboratory Press: New York, 2009.
2. Weis, W. I.; Taylor, M. E.; Drickamer, K. Immunol. Rev. 1998, 163, 19–34. doi:10.1111/j.1600-065X.1998.tb01185.x
3. Glycoproteins and disease. In New comprehensive biochemistry; Montreuil, J.; Vliegenthart, J. F. G.; Schachtler, H., Eds.; Elsevier: Amsterdam, The Netherlands, 1996; Vol. 30.
4. Marquardt, T.; Freeh, H. Biol. Chem. 2001, 382, 161–177. doi:10.1002/1521-3773(20010204)382:2<161::AID-HLCA943>3.0.CO;2-H
5. Hakomori, S. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 10231–10233. doi:10.1073/pnas.172380699.
6. Dennis, J. W.; Laferlé, S.; Waghoorne, C.; Breitman, M. L.; Kerbel, R. S. Science 1987, 236, 582–585. doi:10.1126/science.2953071
7. Ündigil, U. M.; Rini, J. M. Curr. Opin. Struct. Biol. 2000, 10, 510–517. doi:10.1016/S0959-440x(00)00124-x
8. Breton, C.; Fourmel-Gigleux, S.; Palcic, M. M. Curr. Opin. Struct. Biol. 2012, 22, 540–549. doi:10.1016/j.sbi.2012.06.007
9. Hirsch, J.; Koóš, M.; Tvaroška, I. Chem. Pap. 2009, 63, 329–335. doi:10.2478/s11696-009-0008-8
10. Raab, M.; Kozmon, S.; Tvaroška, I. Carbohydr. Res. 2005, 340, 1051–1057. doi:10.1016/j.carres.2005.01.041
11. Look, G. C.; Fotsch, C. H.; Wong, C.-H. Acc. Chem. Res. 1993, 26, 182–190. doi:10.1021/ar00028a008
12. Sears, P.; Wong, C.-H. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 12086–12093. doi:10.1073/pnas.93.22.12086
13. Wang, R.; Steensma, D. H.; Takaoka, Y.; Yun, J. W.; Kajimoto, T.; Wong, C.-H. Bioorg. Med. Chem. 1997, 5, 661–672. doi:10.10109/0068-0896(97)00005-9
14. Sears, P.; Wong, C.-H. Angew. Chem., Int. Ed. 1999, 38, 2300–2304. doi:10.1002/(SICI)1521-3773(19990816)38:16<2300::AID-ANIE2300>3.0.CO;2-6
15. Elhalabi, J. M.; Rice, K. G. Curr. Med. Chem. 1999, 6, 93–116.
16. Waldscheck, B.; Streiff, M.; Notz, W.; Kinzy, W.; Schmidt, R. R. Angew. Chem., Int. Ed. 2001, 40, 4007–4011. doi:10.1002/1521-3773(20011110)40:21<4007::AID-ANIE4007>3.0.CO;2-F
17. Compain, P.; Martin, O. R. Bioorg. Med. Chem. 2001, 9, 3077–3092. doi:10.1016/S0968-0896(01)00178-5
18. Tvaroška, I.; André, I.; Carver, J. P. J. Am. Chem. Soc. 2000, 122, 8762–8766. doi:10.1021/ja001525u
19. Tvaroška, I.; André, I.; Carver, J. P. Glycobiology 2003, 13, 559–566. doi:10.1093/glycob/wo687
20. Schmidt, O. T. Methods Carbohydr. Chem. 1963, 2, 318–324.
21. Shen, X.; Wu, Y.-L.; Wu, Y. Helv. Chim. Acta 2000, 83, 943–953. doi:10.1002/(SICI)1522-2675(20000510)83:5<943::AID-HLCA943>3.0.CO;2-H
22. Frick, W.; Krülle, T.; Schmidt, R. R. Liebig Ann. Chem. 1991, 435–438. doi:10.1515/lieb199119910179
23. Lin, W.; Zhang, X.; He, Z.; Jin, Y.; Gong, L.; Mi, A. Synth. Commun. 2002, 32, 3279–3284. doi:10.1081/scc-120014032
24. SMART & SAINT; Bruker AXS Inc.: Madison, WI, USA, 2003.
25. SHELDRICK, Version 2.10; University of Göttingen: Germany, 2003.
26. Sheldrick, G. M. Acta Crystallogr., Sect. A 2008, 64, 112–122. doi:10.1107/s0108767307043930
27. Gruene, T.; Hahn, H. W.; Luebben, A. V.; Meiller, F.; Sheldrick, G. M. J. Appl. Crystallogr. 2013, 47, 462–466. doi:10.1107/s0021889813006186
28. Cremer, D.; Pople, J. A. J. Am. Chem. Soc. 1975, 97, 1354–1358. doi:10.1021/ja00839a101
29. McNaught, A. D. Pure Appl. Chem. 1996, 68, 1919–2008. doi:10.1351/pac199668101919

License and Terms

This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (http://www.beilstein-journals.org/bjoc)

The definitive version of this article is the electronic one which can be found at: doi:10.3762/bjoc.11.170